Skip to main content

Table 4 Comparison of demographic and clinical data of patients by healthcare system

From: Psychosocial and economic impact of rheumatic diseases on caregivers of Mexican children

  Total
200
n (%)
PartC
147
n (%)
FullC
43
n (%)
PRI
10
n (%)
P value*
Age in years, median (IQR) 13 (10–15) 12 (9–15) 14 (12–16) 13.5 (10.7–15.2) 0.01**
Female 134 (67) 95 (64.6) 32 (74.4) 7 (70) 0.85
Cutaneous symptoms 82/193 (42.5) 71/140 (50.7) 8 (18.6) 3 (30) 0.01
Musculoskeletal symptoms a 161/193 (83.4) 120/140 (85.7) 32 (74.4) 9 (90) 0.19
Systemic symptoms b 62/193 (32.1) 48/140 (34.3) 11 (25.6) 3 (30) 0.56
Treatment NSAID 80/179 (44.7) 70/126 (55.6) 3 (7) 7 (70) <  0.001
DMARD 168/179 (93.9) 122/126 (96.8) 36 (83.7) 10 (100) 0.01
Glucocorticoid 82/179 (45.8) 72/126 (57.1) 7 (16.3) 3 (30) <  0.001
bDMARD 53/179 (29.6) 24/126 (19) 24 (55.8) 5 (50) <  0.001
Hospitalization 97/174 (55.7) 77/121 (63.6) 19 (44.2) 1 (10) 0.01
Disability 43/174 (24.7) 41/121 (33.9) 1 (2.3) 1 (10) <  0.001
Active Disease 87/174 (50) 75/121 (62) 8 (18.6) 4 (40) <  0.001
  1. IQR Interquartile range, PartC Partial Coverage, FullC Total Coverage, PRI Private System
  2. NSAID Nonsteroidal anti-inflammatory drugs, DMARD Disease-modifying antirheumatic, bDMARD Biological therapy
  3. a: Includes arthritis and myositis
  4. b: Includes neurological, hematological, pulmonary, gastrointestinal, cardiovascular, nephritis, serositis, adenomegaly, hepatomegaly, hepatitis, thyroiditis and uveitis manifestations
  5. * Analyzed with Chi square test
  6. ** Analyzed with Kruskal-Wallis test